Preparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline.
Cabergoline
Design-Expert
PEG
Suppository
Vomiting
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
15
08
2023
accepted:
26
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on the stomach. In this regard we developed a cabergoline suppository as an alternative to cabergoline tablets. Design-Expert was used to determine the most suitable concentrations of PEG 6000/400, and Tween 80 to obtain a stable suppository. Specific ratios of PEG6000/400 and Tween 80 were entered as factors, and release, melting time, and hardness were evaluated as responses. In addition, the final formulation was evaluated for weight changes, pH, drug content, degradation time, deformation time, The suppositories were all smooth and white. They all had a weight that averaged less than 5 %. The formulations showed a pH between 6 and 6.5. The active ingredient content ranged between 79.666 ± 8.54 % and 99.67 ± 6.55 %. Suppository stiffness was between 2.74 ± 0.04 and 4.20 ± 0.03. The decomposition time of the suppositories varied between 11.25 ± 0.15 to 20.19 ± 0.08 min. The deformation time was between 26.11 ± 0.06 to 38.59 ± 0.47 min. Cabergoline content was released over 45 min from formulations of F10 (∼46 %), F2 (∼64 %), F6 (∼69 %), F4 (∼79 %), F1 (∼88 %), and F7 (∼93 %). However, other formulations released more than 95 % within 45 min. All variables except melting time significantly affected our responses.
Sections du résumé
Background
UNASSIGNED
There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on the stomach. In this regard we developed a cabergoline suppository as an alternative to cabergoline tablets. Design-Expert was used to determine the most suitable concentrations of PEG 6000/400, and Tween 80 to obtain a stable suppository. Specific ratios of PEG6000/400 and Tween 80 were entered as factors, and release, melting time, and hardness were evaluated as responses. In addition, the final formulation was evaluated for weight changes, pH, drug content, degradation time, deformation time,
Results
UNASSIGNED
The suppositories were all smooth and white. They all had a weight that averaged less than 5 %. The formulations showed a pH between 6 and 6.5. The active ingredient content ranged between 79.666 ± 8.54 % and 99.67 ± 6.55 %. Suppository stiffness was between 2.74 ± 0.04 and 4.20 ± 0.03. The decomposition time of the suppositories varied between 11.25 ± 0.15 to 20.19 ± 0.08 min. The deformation time was between 26.11 ± 0.06 to 38.59 ± 0.47 min. Cabergoline content was released over 45 min from formulations of F10 (∼46 %), F2 (∼64 %), F6 (∼69 %), F4 (∼79 %), F1 (∼88 %), and F7 (∼93 %). However, other formulations released more than 95 % within 45 min.
Conclusions
UNASSIGNED
All variables except melting time significantly affected our responses.
Identifiants
pubmed: 38028218
doi: 10.1016/j.jsps.2023.101849
pii: S1319-0164(23)00344-4
pmc: PMC10663909
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101849Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Endocrinology. 2005 Jul;146(7):2952-62
pubmed: 15817666
AAPS PharmSciTech. 2009;10(4):1321-30
pubmed: 19894122
W V Med J. 2011 Jan-Feb;107(1):12-3
pubmed: 21322466
Expert Opin Pharmacother. 2000 Mar;1(3):555-74
pubmed: 11249538
J Clin Endocrinol Metab. 2007 Aug;92(8):2931-7
pubmed: 17456571
Semin Reprod Med. 2010 Nov;28(6):532-9
pubmed: 21082512
Taiwan J Obstet Gynecol. 2011 Mar;50(1):2-10
pubmed: 21482366
Postgrad Med J. 1997 Aug;73(862):507-8
pubmed: 9307745
Fertil Steril. 2006 Jan;85(1):112-20
pubmed: 16412740
Clin Pharmacokinet. 2003;42(7):633-45
pubmed: 12844325
Hum Reprod. 2001 Nov;16(11):2263-6
pubmed: 11679501
Eur J Pharm Sci. 2021 Feb 1;157:105602
pubmed: 33086117
Endocrinol Metab Clin North Am. 2008 Mar;37(1):67-99, viii
pubmed: 18226731
Endocr J. 1995 Apr;42(2):153-61
pubmed: 7627259
Indian J Pharm Sci. 2013 Sep;75(5):585-90
pubmed: 24403660
Hum Reprod. 2007 Dec;22(12):3210-4
pubmed: 17921134
J Reprod Med. 2015 Jan-Feb;60(1-2):48-54
pubmed: 25745751
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008605
pubmed: 22336848
Acta Pol Pharm. 2010 May-Jun;67(3):217-23
pubmed: 20524422
Indian J Pharm Sci. 2008 Jul-Aug;70(4):498-501
pubmed: 20046779
Drug Deliv. 2016;23(2):550-63
pubmed: 24959937
J Mater Sci Mater Med. 2018 Nov 3;29(11):165
pubmed: 30392146
Reprod Biol Endocrinol. 2015 Sep 17;13:104
pubmed: 26377185
BMJ. 2005 Jul 30;331(7511):292-3
pubmed: 16052024
Reprod Biomed Online. 2008 Dec;17(6):751-5
pubmed: 19079957
Fertil Steril. 1996 Feb;65(2):440-2
pubmed: 8566276
Avicenna J Med. 2015 Oct-Dec;5(4):123-7
pubmed: 26629467
J Psychiatry Neurosci. 2002 Jan;27(1):54
pubmed: 11836977
Obstet Gynecol Surv. 2010 Jul;65(7):462-73
pubmed: 20723268
J Clin Endocrinol Metab. 2009 Jan;94(1):223-30
pubmed: 18957500
Int J Pharm. 2013 Jan 30;441(1-2):218-26
pubmed: 23220079
Fertil Steril. 2014 Mar;101(3):664-75
pubmed: 24360566
Fertil Steril. 2009 Sep;92(3):1168.e1-1168.e4
pubmed: 19539908
AAPS J. 2011 Dec;13(4):519-47
pubmed: 21818695
Pharmaceuticals (Basel). 2016 Mar 11;9(1):
pubmed: 26978373
Hum Reprod Update. 2008 Jul-Aug;14(4):321-33
pubmed: 18385260
J Cell Sci. 2009 Sep 15;122(Pt 18):3385-92
pubmed: 19706677
Org Biomol Chem. 2019 Feb 20;17(8):2055-2069
pubmed: 30667450
Am J Pharm Educ. 2006 Oct 15;70(5):98
pubmed: 17149427
Biol Pharm Bull. 1996 Sep;19(9):1210-3
pubmed: 8889042
Eur J Pharm Sci. 2020 Jan 15;142:105141
pubmed: 31706017